TY - JOUR
T1 - Dermatomyositis, pembrolizumab, and squamous cell carcinoma of the lung
AU - Wiggins, Claire J.
AU - Chon, Susan Y.
N1 - Publisher Copyright:
© Copyright © 2020 Baylor University Medical Center.
PY - 2021
Y1 - 2021
N2 - Cancer immunotherapy has impacted the treatment of numerous tumor types, including skin, lung, and colon cancers. Immune checkpoint inhibitors (ICI) activate the immune system to attack cancer cells, but this mechanism can also impact healthy cells. Dermatomyositis, an autoimmune syndrome affecting multiple organ systems, is often associated with cancer as a paraneoplastic syndrome, but this syndrome can also be induced by ICI. Here, we describe a case of dermatomyositis in a patient receiving pembrolizumab for treatment of squamous cell carcinoma of the lung and discuss the importance of recognizing complications of ICI.
AB - Cancer immunotherapy has impacted the treatment of numerous tumor types, including skin, lung, and colon cancers. Immune checkpoint inhibitors (ICI) activate the immune system to attack cancer cells, but this mechanism can also impact healthy cells. Dermatomyositis, an autoimmune syndrome affecting multiple organ systems, is often associated with cancer as a paraneoplastic syndrome, but this syndrome can also be induced by ICI. Here, we describe a case of dermatomyositis in a patient receiving pembrolizumab for treatment of squamous cell carcinoma of the lung and discuss the importance of recognizing complications of ICI.
KW - Adverse drug reaction
KW - dermatomyositis
KW - immune-related adverse event
KW - immunotherapy
KW - squamous cell carcinoma of the lung
UR - http://www.scopus.com/inward/record.url?scp=85089978397&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85089978397&partnerID=8YFLogxK
U2 - 10.1080/08998280.2020.1811189
DO - 10.1080/08998280.2020.1811189
M3 - Article
C2 - 33456169
AN - SCOPUS:85089978397
SN - 0899-8280
VL - 34
SP - 120
EP - 121
JO - Baylor University Medical Center Proceedings
JF - Baylor University Medical Center Proceedings
IS - 1
ER -